The role of corticosteroids in bronchiolitis and croup
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The introduction of systemic and inhaled topical corticoinvasive in a distressed young child and budesonide at £4.46 for 2 mg is approximately 100 times more expensive steroids may not have significantly reduced mortality from childhood asthma, but it has greatly improved the quality than oral dexamethasone. For acute bronchiolitis, which is caused by respiratory of life for many children and now they have an important and well established role in asthma management. Over the syncytial virus (RSV), it is well established that the disease involves an acute inflammatory process with massive inyears corticosteroids have also been considered as possible treatment for two other forms of airway obstruction -acute vasion of the respiratory tract by neutrophils. 14 It is also generally accepted that bronchiolitis is associated with a risk laryngobronchitis (or croup) and acute bronchiolitis.
The effects of corticosteroids on croup have been so factor of 3-4 for subsequent asthma symptoms, although it remains contentious whether the bronchiolitis itself is dramatic and well documented that the only surprise is that this form of treatment has taken so long to be generally responsible 15 16 or whether those at increased risk for developing severe bronchiolitis, either from a genetic atopy accepted. In 1980 1 a critical assessment of nine studies on the efficacy of systemic corticosteroids was published. Most tendency or subnormal neonatal lung function, 17 are selectively admitted to hospital. Whatever the mechanism, were considered to have unsatisfactory clinical designs and it was concluded that the role of corticosteroids in the bronchiolitis would appear to be a condition that is likely to be modified by corticosteroid therapy. It has always treatment of croup was unproven. The turning point came in 1989 with the publication by Kairys and colleagues 2 of been something of a surprise that in the past, with one exception, 18 no double blind controlled study has shown a meta-analysis of nine placebo controlled trials considered to be satisfactory. Of these, only two of seven showed a measurable benefit. The initial positive study published by Oski and colleagues in abstract form 18 was relatively small, significant advantage for systemic corticosteroids after 12 hours of treatment and two of four at 24 hours. One of involving only 20 infants. Of these, nine received dexamethasone and 11 placebo. The results, however, were the four studies in which children required intubation showed significant protection. Although most of the studies quite striking with a significant reduction in the time on oxygen (25 versus 44 hours) and more rapid discharge failed to show significant effects, in all the studies there was a trend in favour of corticosteroids so that the metafrom hospital (4.4 versus 7.0 days -all failed to show that systemic corticosteroids had any effect on the natural history of acute bronchiolitis. Even At one extreme of severity, oral prednisolone has been shown by the Perth group 3 to reduce the time to extubation Oski et al were unable to confirm their initial findings in a subsequent larger study. 23 As a result of these publications, from a mean of 138 hours to 98 hours, and also the need for reintubation. A further study 4 found that a relatively the Committee on Drugs for the American Academy of Pediatrics concluded in 1970 that "there is no scientific small dose of dexamethasone, 0.15 mg/kg, was as effective as 0.6 mg/kg in relieving symptoms and reducing the time basis for the routine administration of corticosteroids in bronchiolitis". 23 to discharge. Others 5 have compared the effects of corticosteroids with nebulised adrenaline and there are now two Perhaps because of this statement, there were relatively few studies in the next 20 years and the consensus remained randomised studies on the outpatient use of oral corticosteroids, one 6 showing that treatment reduces the need for that systemic steroids had little to offer in the management of bronchiolitis. One study 24 on the effects of steroids and reattendance at the emergency department and the other 7 indicating a more rapid resolution in respiratory symptoms.
2 agonists on the symptoms of 32 wheezy infants, some of whom (number not stated) had bronchiolitis, suggested There has also been increasing interest in the role of inhaled nebulised budesonide in the treatment of croup.
that neither form of treatment had any effect on the rate of resolution of symptoms but that the combination was Three placebo controlled trials have been published, 8-10 all of which showed more rapid resolution in symptoms, and useful. The design of the study was relatively complicated with only eight infants in each treatment cell. Subsequent two reported a reduction in time to discharge. One study 11 has compared nebulised budesonide with oral dexastudies by De Boeck et al 25 and Springer et al 26 (50 infants) were also negative. Perhaps the strongest statement against methasone in a dose of 0.6 mg/kg. Both treatments were superior to placebo with non-significant trends in favour the use of systemic steroids has been provided by a study from Chicago published in the Lancet last year. 27 This of dexamethasone. A further publication 12 in which all the children received oral corticosteroids and were then group recruited 118 infants under the age of 12 months who required admission to hospital for acute bronchiolitis. randomised to receive either budesonide or placebo inhalations showed a reduction in symptoms after four hours in Sixty five received intramuscular dexamethasone (1 mg/kg daily for up to three days) and 53 were given saline the treatment group but no difference in hospital admission rates.
injections as placebo. They were unable to show any effects of steroid therapy on the rate of resolution of symptoms, These studies confirm that both systemic steroids and nebulised budesonide are effective therapies. As stated time in oxygen, or the incidence of respiratory symptoms in the 10-14 days after discharge. recently by Thomson, 13 croup is usually benign and selflimiting so that treatment should be reserved for those
In total contrast, in this issue of Thorax van Woensel et al 28 report the results of a well designed study into the with stridor and recession at rest. Oral corticosteroids would appear to be preferable as administration is less effects of oral prednisolone on respiratory symptoms in group.bmj.com on May 2, 2017 -Published by http://thorax.bmj.com/ Downloaded from infants admitted to the Beatrix Children's Hospital in compared with placebo. Again, wheezing alone was used as the diagnostic criterion and 39% had a first degree Groningen with acute RSV bronchiolitis. All were under 24 months of age (mean 3.6 months). Twenty seven received history of atopy. However, the improvements on active treatment totally disappeared for sodium cromoglycate prednisolone (1 mg/kg/day) and the remaining 27 received placebo. Analysis of the results showed that prednisolone when the atopic infants were removed and were no longer significant for inhaled budesonide. There are at least two reduced the time on mechanical ventilation from a mean of 6.3 to 5.6 days in the 14 infants requiring ventilatory other double blind studies which have failed to show any prophylactic benefit (G Fox, personal communication; P support. Although this was not significant, the time in hospital was also reduced from a mean 17.0 to 11.0 days Seddon, personal communication).
Thus it appears that, in the case of croup (acute laryngo-(p<0.001). In the 40 infants with less severe bronchiolitis, prednisolone therapy was associated with more rapid resbronchitis), corticosteroids given systemically or by inhalation are useful in the management of those children who olution of symptoms over the first three days, an effect which was significant, but the time in hospital was only require admission to hospital. For acute bronchiolitis, however, for the reasons outlined above the role of these reduced by one day (7.3 versus 8.3 days). When the analysis was restricted to the 13 infants with high initial drugs remains less certain. Inhaled corticosteroids are helpful in the management of post-bronchiolitic asthma sympsymptom scores (seven on prednisolone and six on placebo) the differences in the rate of recovery were more marked toms but further positive studies are needed before prophylactic courses can be recommended for use im-(p<0.02) but the time in hospital remained similar (7.7 versus 8.0 days). The authors, who appear to be unaware mediately after acute bronchiolitis. of the Chicago study, 27 suggest that their study has been almost uniquely positive because others have either failed accessory muscles. This will inevitably include infants pre- study will now need to be planned to resolve this con- acute bronchiolitis failed to confirm any of these claims (P 
